Epinephrine Dose: Optimal Versus Standard Evaluation Trial
The objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of-hospital cardiac arrest (OHCA) patients
| Condition(s) | Cardiac Arrest, Out-Of-Hospital, Sudden Cardiac Arrest, Ventricular Fibrillation, Ventricular Tachycardia-Pulseless |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | The objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of-hospital cardiac arrest (OHCA) patients. |
| Who can participate | Inclusion Criteria: * Out-of-hospital cardiac arrest treated by paramedics * Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessed by EMS (paramedic or fire) * Established intravenous vascular access Exclusion Criteria: * Known or apparent age \<18 years * Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics * Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.) * Administration of intramuscular, endotracheal tube, or intraosseous epinephrine * Prisoners or persons in police custody * Known allergy or sensitivity to epinephrine |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Unity Health Toronto |
| Locations | Victoria, British Columbia, Canada; Brampton, Ontario, Canada; London, Ontario, Canada; Oakville, Ontario, Canada; Ottawa, Ontario, Canada; Thunder Bay, Ontario, Canada (+2 more sites) |
| Start date | 2023-05-24 |
| NCT ID | NCT03826524 |
| Official listing | https://clinicaltrials.gov/study/NCT03826524 |